Veracyte (VCYT)
(Delayed Data from NSDQ)
$31.94 USD
+0.32 (1.01%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $31.93 -0.01 (-0.03%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.94 USD
+0.32 (1.01%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $31.93 -0.01 (-0.03%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum B VGM
Zacks News
4 Must-Buy Efficient Stocks to Enrich Your Portfolio
by Santanu Roy
Invest in companies like Veracyte (VCYT), Signet Jewelers (SIG), UMB Financial (UMBF) and NVIDIA (NVDA) to make the most of higher efficiency levels.
Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
by Zacks Equity Research
Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
by Nalak Das
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.
Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?
by Zacks Equity Research
Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Veracyte (VCYT) points to a 39.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings
by Moumi Mondal
Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
by Zacks Equity Research
Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.
Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 54.55% and 3.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
by Zacks Equity Research
Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 42.86% and 2.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Instruments Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
The Zacks Medical - Instruments industry is gaining from the rising demand for digital health offers. However, inflation and staffing shortages continue to disrupt growth. HOLX, MASI and VCYT appear well-poised to brave the challenges.
The Zacks Analyst Blog Highlights Palantir Technologies, Veracyte, PagerDuty, Roku and UiPath
by Zacks Equity Research
Palantir Technologies, Veracyte, PagerDuty, Roku and UiPath are part of the Zacks top Analyst Blog.
5 Top-Ranked Cathie Wood Stocks to Buy Right Now
by Aniruddha Ganguly
Here, we have picked five Cathie Wood stocks, Palantir (PLTR), Veracyte (VCYT), PagerDuty (PD), Roku (ROKU) and UiPath (PATH), which are well-poised for healthy returns in 2024.
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 25% and 7.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
RxSight, Inc. (RXST) delivered earnings and revenue surprises of 14.89% and 8.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 23.53% and 17.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 21.43% and 6.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 66.67% and 6.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Best Momentum Stocks to Buy for January 24th
by Zacks Equity Research
VIPS, VCYT and EVR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 24, 2023.
Terex and Armstrong World Industries have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Terex and Armstrong World Industries are part of the Zacks Bull and Bear of the Day article.
3 Medical Instruments Stocks on Recovery Path After Dismal 2022
by Indrajit Bandyopadhyay
Here we discuss three medical instruments stocks - TCMD, VCYT and NVCN - that have started to recover in the past few months after declining for the major part of 2022.
What Makes Veracyte (VCYT) a New Buy Stock
by Zacks Equity Research
Veracyte (VCYT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Veracyte (VCYT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 50% and 12.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?